Abstract: This invention provides high unit density arrays of microparticles and methods of assembling such arrays. The microparticles in the arrays may be functionalized with chemical or biological entities specific to a given target analyte. The high unit density arrays of this invention are formed on chips which may be combined to form multichip arrays according to the methods described herein. The chips and/or multichip arrays of this invention are useful for chemical and biological assays.

Abstract: The invention relates to a control preparation (e.g. comprising microorganism control cells embedded in a cold polymerising resin or plastic) for use in a method for detection of a target microorganism in microbiological pathology, comprising a plurality of section bodies joint by a joining polymer, wherein each section body comprises a matrix polymer (e.g. a cold polymerising resin or plastic). A first section body comprises a nucleic acid sequence specific for the target microorganism (e.g. microorganism cells used as positive control). A second section body comprises a second nucleic acid sequence, which in comparison to said first nucleic acid sequence, contains a deletion, an additional nucleoside or a different nucleoside in one, two, three or four positions of said second nucleic acid sequence and which does not hybridize to said first nucleic acid sequence under stringent conditions (e.g.

Abstract: The present invention provides nucleic acid amplification systems and methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results.

Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.

Abstract: The present invention provides modified oligonucleotides and methods for their use in the detection of nucleic acids. The oligonucleotides and methods find particular application in amplifying and/or detecting areas of genetic variation in target nucleic acid sequences.

Abstract: Methods, systems and media for providing genomic services are disclosed. In one example, a system comprises genomic sequencing equipment configured to generate sequence reads based upon a biological sample obtained from a user, and a genomic services platform. The platform includes a network interface through which the sequence reads are received. A bioinformatics processing pipeline includes a read alignment module configured to generate observed sequence data by aligning the sequence reads relative to a reference sequence, and a variant calling module is operative to identify observed variants in the observed sequence data. Genomic data storage contains the observed variants in the observed sequence data. A variant storage module is disposed to receive a query from network infrastructure of a partner application provider and to provide genomic information based on or derived from the observed variants in response to the query.

Abstract: Methods, compositions, and systems are provided for characterization of modified nucleic acids. In certain preferred embodiments, single molecule sequencing methods are provided for identification of modified nucleotides within nucleic acid sequences. Modifications detectable by the methods provided herein include chemically modified bases, enzymatically modified bases, abasic sites, non-natural bases, secondary structures, and agents bound to a template nucleic acid.

Abstract: Under one aspect, a device is provided for use in luminescent imaging. The device can include a photonic superlattice including a first material, the first material having a first refractive index. The first material can include first and second major surfaces and first and second pluralities of features defined through at least one of the first and second major surfaces, the features of the first plurality differing in at least one characteristic from the features of the second plurality. The photonic superlattice can support propagation of a first wavelength and a second wavelength approximately at a first angle out of the photonic superlattice, the first and second wavelengths being separated from one another by a first non-propagating wavelength that does not selectively propagate at the first angle out of the photonic superlattice.

Abstract: This disclosure describes, in one aspect, a method of electric-field-assisted nucleotide sequencing. Generally, the method includes performing an ion-sensitive nucleotide sequencing method, applying an electric field across the device while the nucleotide sequencing reactions are being performed so that ions released by the sequencing reactions are directed to contact with the ion-sensitive detector, and detecting at least a portion of the released ions in contact with the ion-sensitive detector.

Abstract: The present invention relates to methods of determining the sequence of nucleotides in target nucleic acid molecules. Thus, the invention relates to methods of sub-unit sequencing. The methods comprise the use of identification nucleic acid detection entities which specifically hybridize to the target nucleic acid, bind identification tags and have localization tags transiently bind thereto.

Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.

Abstract: The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.

Abstract: Compositions useful for the detection of single molecules in a sample are provided. In some aspects, the disclosure provides a nucleic acid connected to a nucleotide and two or more luminescent labels. In some embodiments, the nucleic acids described herein comprise one or more structural features that provide enhanced fluorescence intensity. In some aspects, methods of sequencing using the labeled nucleotides of the disclosure are provided.

Abstract: The present invention is directed to methods for detection, treatment monitoring, and slowing of aging by quantifying miRNAs in bodily fluids.

Abstract: The present invention pertains to novel analgesics useful for treating mechanical pain. The invention suggests the use of inhibitors of ?-tubulin acetylation for inhibition of neurological sensations that are mediated by sensory neurons. The perception of mechanical pain is can be modulated by altering the ?-tubulin acetylation, in context of the invention in particular by modulation of the expression and/or activity of the enzyme ?-tubulin acetyltransferase (Atat). The invention provides the medical application of ?-tubulin acetyltransferase inhibitors as analgesics and a screening method for the identification of compounds useful in the treatment of pain.

Abstract: A precise measurement of the immunological receptor diversity present in a sample is obtained by sequence analysis. Samples of interest are generally complex, comprising more than 102, 103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012 or more different sequences for a receptor of interest. Immunological receptors of interest include immunoglobulins, T cell antigen receptors, and major histocompatibility receptors. The specific composition of immunological receptor sequence variations in the sample can be recorded and output. The composition is useful for predictive, diagnostic and therapeutic methods relating to the immune capabilities and history of an individual. Such predictions and diagnoses are used to guide clinical decisions.

Abstract: Ancestry has a significant impact on the major and minor alleles found in each nucleotide position within the genome. Due to mechanisms of inheritance, ancestral-specific information contained within the genome is conserved within members of an ancestry. For this reason, individuals within a specific ancestry are more likely to share alleles in their genomes with other members of the same ancestry. Functionally, the combination of alleles at all positions within a group of individuals defines that group as having a common ancestry. Moreover, the aggregation of differences between alleles at all positions distinguishes one ancestry from another. The genomic similarities and differences between ancestries provides a mechanism to generate reference genomes that are specific for each ancestry.

Abstract: The disclosure comprises methods for predicting survival rates in subjects or populations of subject affected by a disease or disorder. The disclosure relates to methods of predicting the likely effect of and/or likely resistance developed from a treatments or combination of treatments. Software so execute the steps disclosed here and computer-implemented methods are also disclosed.

Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Abstract: A method and kit for detecting a genetic variant associated with a disease or disorder, including incompatibility with a pharmaceutical. The method and kit using a first nano-particle coupled to at least one morpholino nucleic acid probe comprising a target complimentary region base sequence that is a perfect match to a genetic variant sequence.

Abstract: Modeling Amyotrophic Lateral Sclerosis (ALS) with human induced pluripotent stem cells (iPSCs) aims to reenact embryogenesis, maturation, and aging of spinal motor neurons (spMNs) in vitro. As the maturity of spMNs grown in vitro compared to spMNs in vivo remains largely unaddressed, it is unclear to what extent this in vitro system captures critical aspects of spMN development and molecular signatures associated with ALS. Here, the Inventors compared transcriptomes among iPSC-derived spMNs, fetal, and adult spinal tissues. The Inventors resolved gene networks and pathways associated with spMN maturation and aging. These networks enriched for familial ALS genetic variants and were affected in sporadic ALS. Altogether, the Inventors' findings suggest that developing strategies to further mature and age iPSC-derived spMNs will provide more effective iPSC models of ALS.

Abstract: The present invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy.

Abstract: Methods of diagnosing and treating disorders related to excess eosinophil numbers or activity, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

Abstract: Provided are: a method for predicting peritoneal dissemination of gastric cancer, and screening a drug that acts selectively on peritoneal dissemination; and a drug. SYT13, SYT8, and ANOS1, which are specifically expressed at high levels in groups with peritoneal dissemination of gastric cancer, are used as indicators, whereby it is possible to predict postoperative peritoneal dissemination and to screen a molecularly targeted therapeutic agent. Furthermore, these siRNAs can suppress peritoneal dissemination recurrence.

Abstract: The present invention relates to a method for the diagnosis of colorectal cancer from a sample of blood or blood fractions, and to a kit for said diagnosis.

Abstract: A noninvasive method for early detection of a precancerous lesion that may be developed into oral cancer by large-scale screening is provided. The method is a method for obtaining data for diagnosis of an oral precancerous lesion in a subject by detecting methylation of DNA in gargled fluid collected from the subject, wherein the DNA is DNA in a promoter region of at least one gene selected from the following group of genes: RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, HIC1, CASP8, RAR?, CDKN2B, CHFR, ATM, CDKN1B, BRCA1, and CADM1.

Abstract: Disclosed are targeted anti-proliferative approaches for breast cancer utilizing CDK7 inhibitors having efficacy in multiple subtypes of breast cancer, including but without limitation to ER-positive, HER2-positive and Triple Negative Breast Cancer. Methods utilize CDK7 inhibitors alone as well in conjunction with EGFR inhibitors, which provides synergistic anti-proliferative effects on breast cancer cells across a broad spectrum of breast cancer subtypes. Methods for determining sensitivity of breast cancer subtypes to CDK7 inhibitors based upon CITED2 expression levels are also described.

Abstract: The present invention relates to a kit (a) comprising or (b) consisting of means for detecting and/or quantifying one, two, three or all four of the following miRNAs: hsa-miR-615-5p; hsa-miR-125a-5p; hsa-let-7a-5p; and hsa-let-7b-5p.

Abstract: Methods and kits to distinguish metastatic-lethal prostate cancer (PCa) from indolent PCa in a subject are described. The methods and kits utilize the methylation status of genetic markers. Distinguishing metastatic-lethal PCa from indolent PCa informs more directed treatments at an earlier time point than previously available.

Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Abstract: The present invention relates to methods for predicting pancreatic cancer treatment response.

Abstract: A pocket former may include a pocket former body, the pocket former body having an outer surface. The pocket former may further include a collapsible element, the collapsible element formed on the outer surface of the pocket former body. The collapsible element may extend radially outwardly from the pocket former body.

Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as a adenoma or an adeocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinoma.

Abstract: Methods for the rapid detection of the presence or absence of Babesia in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting Babesia and kits are provided that are designed for the detection of Babesia, including, but not limited to, the Babesia species of B. microti, B. divergens, B. duncani, and B. venatorum. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of Babesia.

Abstract: The invention relates to a method of identifying a specific yeast species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the yeast species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the yeast species, and specifically identifying the yeast species. The invention also relates to a method of identifying a yeast mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the yeast mycotoxin from the patient tissue or body fluid, contacting the yeast mycotoxin with an antibody directed against the yeast mycotoxin, and identifying the yeast myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a yeast infection, and to develop an effective treatment regimen for the patient.

Abstract: The disclosure relates to methods and compositions for identifying and/or selecting soybean plants that have resistance to lodging, have improved resistance to lodging, or are susceptible to lodging. The methods use molecular genetic markers to identify, select and/or construct resistant plants or identify and counter-select susceptible plants. Also provided are soybean plants that display resistance or improved resistance to lodging that are generated by the methods described herein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.

Abstract: In an aspect, the invention relates to nucleic acids encoding new bisabolol responsive biosensor polypeptides useful for detecting responses to stimuli, identifying new enzymes, and novel pathways in cells. In other aspects, the invention relates to genes which induce expression in response to bisabolol and the gene products encoded by those genes. In still another aspect, the invention relates to control regions that induce expression in response to bisabolol. In an aspect, the invention also relates to the use of the bisabolol responsive biosensors, bisabolol responsive control regions, and the genes and encoded polypeptides that are expressed in response to bisabolol.

Abstract: A method of detecting Enterovirus D68 is provided. The method may include adding to a mixture containing the sample from the subject, (a) a first forward primer comprising SEQ ID NO: 1, (b) a second forward primer comprising SEQ ID NO: 2, (c) a third forward primer comprising SEQ ID NO: 3, (d) a first reverse primer comprising SEQ ID NO: 4, and (e) a second reverse primer comprising SEQ ID NO: 5, subjecting the mixture to conditions that allow nucleic acid amplification, and detecting the presence or absence of Enterovirus D68 by analyzing the nucleic acid amplification products. The forward primers may include a first universal tail sequence and reverse primers may include a second universal tail sequence. The nucleic acid amplification products may be sequenced using next-generation sequencing.

Abstract: Methods and oligonucleotide reagents for diagnosing chikungunya virus and Zika virus infections are described. In particular, the invention relates to quantitative assays that can detect all lineages of chikungunya virus and Zika virus and distinguish chikungunya virus and Zika virus from each other as well as dengue virus and other arbovirus pathogens.

Abstract: A method for obtaining crystals from a mother solution operates such that mother solution is fed into a crystallisation device. Supersaturation of the mother solution is brought about by open and/or closed-loop control of the temperature (?). Seed crystals are added to the mother solution at a seeding point (Sp). The seed crystals are grown as nuclei by continuous closed-loop process control and are finally removed from the method as crystals. They form the product yield. The formation of crystal nuclei in the mother solution is countered by steps in the closed-loop process control. During the closed-loop process control and the crystallisation procedure, the position of the limit (M) of the formation of secondary nuclei is determined using sensors that detect data currently, wherein the position of the limit (M) is established as a value of the concentration (c) and the temperature (?) from these data.

Abstract: Provided is a hexavalent chromium treatment agent capable of penetrating inside of a leather and capable of reducing not only hexavalent chromium present in the vicinity of the surface of the leather but also hexavalent chromium present inside the leather into trivalent chromium. The hexavalent chromium treatment agent of the present invention comprises a hexavalent chromium-reducing compound capable of reducing hexavalent chromium into trivalent chromium, a nonionic surfactant, and an aqueous solvent. The hexavalent chromium-reducing compound preferably comprises an organic compound (A) that has a specific structure capable of acting to reduce hexavalent chromium into trivalent chromium, that has a hydroxyphenyl group, and that has no aldehyde groups and no carboxyl groups.

Abstract: High-entropy alloy, particularly a precipitation hardening high entropy alloy, is provided as a component material used in electromagnetic, chemical, shipbuilding, mechanical, and other applications, a component material used in extreme environments requiring high strength and good corrosion resistance, and the like.

Abstract: In one or more first regions of a steel component, a primarily austenitic microstructure can be produced from which a mainly martensitic microstructure can be brought about through a quenching process. In one or more second regions of the component, a mainly ferritic-pearlitic microstructure can be brought about. In one or more third regions, a mainly bainitic microstructure can be brought about. The component is first heated to a temperature below the AC3 temperature in a first furnace, and transferred into a treatment station. The component can be cooled during the transfer. In the treatment station, the first and third regions are brought to a temperature above the austenitization temperature. Only the third regions are cooled to a cooling stop temperature ?s. The component is transferred into a second furnace, with a temperature lying below the AC3 temperature. There, the temperatures of the three different regions approximate one another.

Abstract: A high strength forged steel comprises composition which comprises predetermined amounts of predetermined chemical elements and a balance being Fe and inevitable purities. A major constituent of a metallographic structure of the steel comprises bainite, martensite or a combination thereof. An average crystal grain size in steel microstructures between a near-surface level below a surface of the steel at a distance of 5 mm and a mid level below the surface at a distance of one quarter of the thickness of the steel is less than or equal to 50 ?m. A difference between peak values of crystal grain size distributions at the near-surface level and the mid level is greater than or equal to 10 ?m and less than or equal to 30 ?m. The total index as determined in accordance with DIN 50602-1985, method K0 for evaluating non-metallic inclusions is preferably less than or equal to 10.

Abstract: The high-strength seamless steel pipe has a volume fraction of tempered martensite of 95% or more, and a prior austenite size number of 8.5 or more, and contains nitride inclusions having a size of 4 ?m or more and whose number is 100 or less per 100 mm2, nitride inclusions having a size of less than 4 ?m and whose number is 700 or less per 100 mm2, oxide inclusions having a size of 4 ?m or more and whose number is 60 or less per 100 mm2, and oxide inclusions having a size of less than 4 ?m and whose number is 500 or less per 100 mm2, in a cross section perpendicular to a rolling direction.

Abstract: An oriented electrical steel sheet according to an exemplary embodiment of the present invention includes Si: 2.0 to 7.0%, C: 0.005% or less (excluding 0%), Al: 0.05% or less (excluding 0%), N: 0.005% or less (excluding 0%), S: 0.005% or less (excluding 0%), a content of each of Ba and Y or a sum thereof: 0.001 to 0.3%, and Fe and other unavoidable impurities as a balance by wt %.

Abstract: The invention relates to a method for heat treating a metal component. The invention relates in particular to an application in the partial hardening of optionally pre-coated components made of high-strength manganese-boron steel. With the method, at least one first sub-region of the component is convectively cooled by means of at least one nozzle, which discharges a fluid stream to the first sub-region so that a temperature difference of at least 100 K is set between the at least one first sub-region and at least one second sub-region of the component, wherein the at least one nozzle is operated with a positive pressure of at least 2 bar.

Abstract: A dual hardness steel article comprises a first air hardenable steel alloy having a first hardness metallurgically bonded to a second air hardenable steel alloy having a second hardness. A method of manufacturing a dual hard steel article comprises providing a first air hardenable steel alloy part comprising a first mating surface and having a first part hardness, and providing a second air hardenable steel alloy part comprising a second mating surface and having a second part hardness. The first air hardenable steel alloy part is metallurgically secured to the second air hardenable steel alloy part to form a metallurgically secured assembly, and the metallurgically secured assembly is hot rolled to provide a metallurgical bond between the first mating surface and the second mating surface.

Abstract: Iron loss is reduced by increasing magnetic flux density. A non-oriented electrical steel sheet has a chemical composition containing, by mass %, C: 0.0050% or less, Si: 1.50% or more and 4.00% or less, Al: 0.500% or less, Mn: 0.10% or more and 5.00% or less, S: 0.0200% or less, P: 0.200% or less, N: 0.0050% or less, and O: 0.0200% or less, with the balance consisting of Fe and inevitable impurities, in which the steel sheet has an Ar3 transformation temperature of 700° C. or higher, a grain size of 80 ?m or more and 200 ?m or less, a Vickers hardness of 140 HV or more and 230 HV or less.